Erratum
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Tags: Erratum Source Type: research

Multi-Isotope Capabilities of a Small-Animal Multi-Pinhole SPECT System
Conclusion: The NanoSPECT/CTPLUS enables the simultaneous acquisition of 3 radioisotopes with high quantitative accuracy and only little loss of image quality when the activity ratio is adapted to isotope-specific count rate sensitivities and when the system calibration is performed with phantoms of appropriate size. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Lukas, M., Kluge, A., Beindorff, N., Brenner, W. Tags: Basic Source Type: research

PennPET Explorer: Human Imaging on a Whole-Body Imager
Conclusion: These studies provided a proof of concept for many proposed applications for a PET scanner with a long axial field of view. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Pantel, A. R., Viswanath, V., Daube-Witherspoon, M. E., Dubroff, J. G., Muehllehner, G., Parma, M. J., Pryma, D. A., Schubert, E. K., Mankoff, D. A., Karp, J. S. Tags: Translational Source Type: research

PennPET Explorer: Design and Preliminary Performance of a Whole-Body Imager
Conclusion: The physical performance measurements validated the system design and led to high-quality human studies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Karp, J. S., Viswanath, V., Geagan, M. J., Muehllehner, G., Pantel, A. R., Parma, M. J., Perkins, A. E., Schmall, J. P., Werner, M. E., Daube-Witherspoon, M. E. Tags: Translational Source Type: research

Image Quality and Semiquantitative Measurements on the Biograph Vision PET/CT System: Initial Experiences and Comparison with the Biograph mCT
This study evaluated the initial experiences with this new PET/CT system in terms of perceived image quality and semiquantitative analysis in comparison to the Biograph mCT as a reference. Methods: In total, 20 oncologic patients were enrolled and received a single 3 MBq/kg injected dose of 18F-FDG followed by a dual-imaging PET scan. Ten patients were scanned on the Biograph mCT first, whereas the other 10 patients were scanned on the Biograph Vision first. The locally preferred clinically reconstructed images were blindly reviewed by 3 nuclear medicine physicians and scored (using a Likert scale of 1–5) on tumor le...
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: van Sluis, J., Boellaard, R., Somasundaram, A., van Snick, P. H., Borra, R. J. H., Dierckx, R. A. J. O., Stormezand, G. N., Glaudemans, A. W. J. M., Noordzij, W. Tags: Clinical Source Type: research

64Cu PET Imaging of the CXCR4 Chemokine Receptor Using a Cross-Bridged Cyclam Bis-Tetraazamacrocyclic Antagonist
Conclusion: The tetraazamacrocyclic small molecule 64Cu-CuCB-bicyclam has been shown to be an imaging agent for the CXCR4 receptor that is likely to be applicable across a range of species. It has high affinity and stability and is suitable for preclinical research in immunocompetent murine models. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Burke, B. P., Miranda, C. S., Lee, R. E., Renard, I., Nigam, S., Clemente, G. S., DHuys, T., Ruest, T., Domarkas, J., Thompson, J. A., Hubin, T. J., Schols, D., Cawthorne, C. J., Archibald, S. J. Tags: Basic Source Type: research

PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
Conclusion: 68Ga-NOTA-Nb109 holds great potential for noninvasive PET imaging of the PD-L1 status in tumors and for timely evaluation of the effect of immune checkpoint targeting treatment. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Lv, G., Sun, X., Qiu, L., Sun, Y., Li, K., Liu, Q., Zhao, Q., Qin, S., Lin, J. Tags: Basic Source Type: research

PET-Based Human Dosimetry of 68Ga-NODAGA-Exendin-4, a Tracer for {beta}-Cell Imaging
Conclusion: Our human PET/CT-based dosimetric calculations show that the effective radiation doses from the novel tracer 68Ga-NODAGA-exendin-4 are very low for adults and children. The doses are lower than reported for other polypeptide tracers such as somatostatin analogs (2.1–2.6 mSv/100 MBq) and are beneficial for application as a research tool, especially when repeated examinations are needed. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Boss, M., Buitinga, M., Jansen, T. J. P., Brom, M., Visser, E. P., Gotthardt, M. Tags: Clinical Source Type: research

Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics
Conclusion: Despite the heterogeneous patient cohort, logistic regression TCP models showed a strong association between various dose metrics and the probability of response. The performance of mean AD was comparable to that of radiobiologic dose metrics that involve more complex calculations. These results demonstrate the importance of considering TCP in treatment planning for radioembolization. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Dewaraja, Y. K., Devasia, T., Kaza, R. K., Mikell, J. K., Owen, D., Roberson, P. L., Schipper, M. J. Tags: Clinical Source Type: research

Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain: 18F-BCPP-EF, 11C-SA-4503, and 11C-UCB-J
Conclusion: These ligands can be assessed for their potential to stratify patients or monitor the progression of molecular neuropathology in neurodegenerative diseases. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Mansur, A., Rabiner, E. A., Comley, R. A., Lewis, Y., Middleton, L. T., Huiban, M., Passchier, J., Tsukada, H., Gunn, R. N., for the MIND-MAPS Consortium Tags: Translational Source Type: research

Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with 223Ra: The Role of Bystander Effects and Their Potential for Therapy
Conclusion: Taken together, these results support the participation of 223Ra-induced antiproliferative/cytotoxic bystander effects in delayed growth of DTC xenografts. They indicate that the delay depends on the injected activity and therefore is dose-dependent. They suggest using 223RaCl2 as an adjuvant treatment for select patients at early stages of breast cancer. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Leung, C. N., Canter, B. S., Rajon, D., Back, T. A., Fritton, J. C., Azzam, E. I., Howell, R. W. Tags: Basic Source Type: research

Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer
Conclusion: 203Pb-L1–203Pb-L5 demonstrated favorable pharmacokinetics for 212Pb-based TRT. The antitumor efficacy of 212Pb-L2 supports the corresponding 203Pb/212Pb theranostic pair for PSMA-based α-particle TRT in advanced PC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Banerjee, S. R., Minn, I., Kumar, V., Josefsson, A., Lisok, A., Brummet, M., Chen, J., Kiess, A. P., Baidoo, K., Brayton, C., Mease, R. C., Brechbiel, M., Sgouros, G., Hobbs, R. F., Pomper, M. G. Tags: Basic Source Type: research

Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
Conclusion: The 64Cu-labeled PSMA ligands are promising agents to target PSMA and visualize PSMA-positive tumor lesions as shown in preclinical evaluation by small-animal PET studies, organ distribution, and a patient application. Most importantly, the images obtained at 20 h enabled delineation of unclear lesions, showing that the compounds fulfill the prerequisite for dosimetry in the course of therapy planning with 67Cu. Thus, we suggest clinical use of copper-labeled CA003 for diagnostics and radiotherapy of prostate cancer. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Carlos dos Santos, J., Beijer, B., Bauder-Wust, U., Schafer, M., Leotta, K., Eder, M., Benešova, M., Kleist, C., Giesel, F., Kratochwil, C., Kopka, K., Haberkorn, U., Mier, W. Tags: Basic Source Type: research

Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience with a series of 73 castration-resistant prostate carcinoma patients treated with 225Ac-PSMA-617, identifying variables predictive for overall survival (OS) and progression-free survival (PFS) after 225Ac-PSMA-617 treatment. Methods: 225Ac-PSMA-617 was administered to patients who had metastatic castration-resistant prostate carcinoma and who had exhausted available therapy options for their disease. Full blood count, glomerular...
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., Lengana, T., Giesel, F. L., Van de Wiele, C., Morgenstern, A. Tags: Clinical Source Type: research

Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer
Conclusion: In this prospective study using the prostate-specific membrane antigen–targeted PET agent 18F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Rowe, S. P., Campbell, S. P., Mana-Ay, M., Szabo, Z., Allaf, M. E., Pienta, K. J., Pomper, M. G., Ross, A. E., Gorin, M. A. Tags: Clinical Source Type: research

Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy
18F-labeled prostate-specific membrane antigen (PSMA)–ligand PET has several principal advantages over 68Ga-PSMA-11. The purpose of this retrospective study was to evaluate the frequency of non–tumor-related uptake and the detection efficacy comparing 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT in recurrent prostate cancer (PC) patients. Methods: The study included 102 patients with biochemically recurrent PC after radical prostatectomy undergoing 18F-PSMA-1007 PET/CT imaging. On the basis of various clinical variables, patients with corresponding 68Ga-PSMA-11 PET/CT scans were matched. All PET/CT scans (n = 2...
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Rauscher, I., Kronke, M., Konig, M., Gafita, A., Maurer, T., Horn, T., Schiller, K., Weber, W., Eiber, M. Tags: Clinical Source Type: research

Lymph Node Involvement in Treatment-Naive Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management
Conclusion: For treatment-naïve prostate cancer patients, PSMA PET/CT is well suited for the detection of nodal metastases. However, the original Roach formula can still be used for a quick assessment of potential lymphatic spread in daily clinical routine. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Koerber, S. A., Stach, G., Kratochwil, C., Haefner, M. F., Rathke, H., Herfarth, K., Kopka, K., Holland-Letz, T., Choyke, P. L., Haberkorn, U., Debus, J., Giesel, F. L. Tags: Clinical Source Type: research

18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome
Conclusion: Combining MTV with a parameter reflecting the tumor burden dissemination further improves DLBCL patient risk stratification at staging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Cottereau, A.-S., Nioche, C., Dirand, A.-S., Clerc, J., Morschhauser, F., Casasnovas, O., Meignan, M., Buvat, I. Tags: Clinical Source Type: research

Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study
Conclusion: Reduction in metabolic ITH during palliative chemotherapy in advanced pancreatic cancer patients is associated with treatment response and might be predictive of PFS and OS. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Yoo, S. H., Kang, S. Y., Cheon, G. J., Oh, D.-Y., Bang, Y.-J. Tags: Clinical Source Type: research

Pulmonary Lymphangitic Carcinomatosis: Diagnostic Performance of High-Resolution CT and 18F-FDG PET/CT in Correlation with Clinical Pathologic Outcome
The rationale of this study was to investigate the performance of high-resolution CT (HRCT) versus 18F-FDG PET/CT for the diagnosis of pulmonary lymphangitic carcinomatosis (PLC). Methods: In this retrospective institution-approved study, 94 patients addressed for initial staging of lung cancer with suspicion of PLC were included. Using double-blind analysis, we assessed the presence of signs favoring PLC on HRCT (smooth or nodular septal lines, subpleural nodularity, peribronchovascular thickening, satellite nodules, lymph node enlargement, and pleural effusion). 18F-FDG PET/CT images were reviewed to qualitatively evalua...
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Jreige, M., Dunet, V., Letovanec, I., Prior, J. O., Meuli, R. A., Beigelman-Aubry, C., Schaefer, N. Tags: Clinical Source Type: research

From the Literature
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

Multiparametric 18F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer?
The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board–approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: br...
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Leithner, D., Helbich, T. H., Bernard-Davila, B., Marino, M. A., Avendano, D., Martinez, D. F., Jochelson, M. S., Kapetas, P., Baltzer, P. A. T., Haug, A., Hacker, M., Tanyildizi, Y., Morris, E. A., Pinker, K. Tags: Clinical Source Type: research

ACMUI Membership
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

SNMMI Leadership Update: The Key to the Future: Reaching Out Early to Medical Students
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Dilsizian, V. Tags: SNMMI Newsline Source Type: research

Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance
By contributing to noninvasive molecular imaging and radioguided surgery, nuclear medicine has been instrumental in the realization of precision medicine. During the last decade, it has also become apparent that nuclear medicine (e.g., in the form of bimodal/hybrid tracers) can help to empower fluorescence-guided surgery. More specifically, when using hybrid tracers, lesions can be noninvasively identified and localized with a high sensitivity and precision (guided by the radioisotope) and ultimately resected under real-time optical guidance (fluorescent dye). This topical review discusses early clinical successes, preclin...
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: van Leeuwen, F. W. B., Schottelius, M., Brouwer, O. R., Vidal-Sicart, S., Achilefu, S., Klode, J., Wester, H.-J., Buckle, T. Tags: Focus on Molecular Imaging Source Type: research

SNMMI Newsline
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

2019 SNMMI Highlights Lecture: Oncology and Therapy
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Scott, A. Tags: SNMMI Newsline Source Type: research

This Month in JNM
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Tags: This Month in JNM Source Type: research

Prostate-Specific Membrane Antigen-Guided Surgery
Since its introduction to the diagnostic pathway for prostate cancer management, prostate-specific membrane antigen (PSMA)–ligand PET has demonstrated great potential. PSMA-ligand imaging is increasingly influencing therapeutic decision making, although its impact on patient outcomes still needs to be defined. One relatively new application, enabled through chemical and engineering efforts, is PSMA-guided surgery. This review highlights the potential of PSMA-guided surgery and discusses its implications in lymph node dissection in primary and recurrent prostate cancer. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Maurer, T., Graefen, M., van der Poel, H., Hamdy, F., Briganti, A., Eiber, M., Wester, H.-J., van Leeuwen, F. W. B. Tags: The State of the Art Source Type: research

Discussions with Leaders: A Conversation Between Martin Pomper and Peter Choyke
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Pomper, M. G., Choyke, P. L. Tags: Discussions with Leaders Source Type: research

The AQARA Principle: Proposing Standard Requirements for Radionuclide-Based Images in Medical Journals
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 2, 2020 Category: Nuclear Medicine Authors: Weber, W. A., Bengel, F. M., Blasberg, R. G. Tags: Editorials Source Type: research

Reply: Off-Target Report on 18F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Zacho, H. D., Petersen, L. J. Tags: Letters Source Type: research

Off-Target Report on 18F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Hoilund-Carlsen, P. F., Alavi, A. Tags: Letters Source Type: research

Reply: Quantification of 18F-DCFPyL Uptake: TBR Versus Patlaks Analysis
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Jansen, B. H. E., Yaqub, M., Cysouw, M. C. F., Vis, A. N., van Moorselaar, R. J. A., Hendrikse, N. H., Hoekstra, O. S., Boellaard, R., Oprea-Lager, D. E. Tags: Letters Source Type: research

Quantification of 18F-DCFPyL Uptake: TBR Versus Patlaks Analysis
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Laffon, E., de Clermont, H., Marthan, R. Tags: Letters Source Type: research

Radiopharmaceutical Chemistry
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Jeong, J. M. Tags: Book Reviews Source Type: research

89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo
Conclusion: This study shows that nonspecific uptake of mAbs for tissues without target expression can be quantified using 89Zr-immuno-PET at multiple time points. These results form a crucial base for measurement of target engagement by therapeutic antibodies in vivo with 89Zr-immuno-PET. For future studies, a pilot phase including at least 3 scans at 1 or more days after injection is required to assess nonspecific uptake as a function of time, to optimize study design for detection of target engagement. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Jauw, Y. W. S., ODonoghue, J. A., Zijlstra, J. M., Hoekstra, O. S., Menke-van der Houven van Oordt, C. W., Morschhauser, F., Carrasquillo, J. A., Zweegman, S., Pandit-Taskar, N., Lammertsma, A. A., van Dongen, G. A. M. S., Boellaard, R., Weber, W. A., Hui Tags: Translational Source Type: research

Performance Evaluation of a High-Resolution Nonhuman Primate PET/CT System
Conclusion: The results obtained from phantom experiments and 1 representative PET measurement in an NHP confirm that the LFER 150 is a high-resolution PET/CT system with suitable performance for brain imaging in NHPs. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Sarnyai, Z., Nagy, K., Patay, G., Molnar, M., Rosenqvist, G., Toth, M., Takano, A., Gulyas, B., Major, P., Halldin, C., Varrone, A. Tags: Basic Source Type: research

The Characterization of 18F-hGTS13 for Molecular Imaging of xC- Transporter Activity with PET
Conclusion: 18F-hGTS13-isomer2 is a new PET radiotracer for molecular imaging of xC– activity that may provide information on tumor oxidation states. 18F-hGTS13-isomer2 has potential for clinical translation for imaging cancers of the thorax because of the low background signal in healthy tissue. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Beinat, C., Gowrishankar, G., Shen, B., Alam, I. S., Robinson, E., Haywood, T., Patel, C. B., Azevedo, E. C., Castillo, J. B., Ilovich, O., Koglin, N., Schmitt-Willich, H., Berndt, M., Mueller, A., Zerna, M., Srinivasan, A., Gambhir, S. S. Tags: Basic Source Type: research

PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms
Conclusion: PARaDIM extends the use of Monte Carlo dose calculations to the broader community in nuclear medicine by providing a user-friendly graphical user interface for calculation setup and execution. PARaDIM leverages the enhanced anatomic realism provided by advanced computational reference phantoms or bespoke image-derived phantoms to enable improved assessments of radiation doses in a variety of radiopharmaceutical use cases, research, and preclinical development. PARaDIM can be downloaded freely at www.paradim-dose.org. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Carter, L. M., Crawford, T. M., Sato, T., Furuta, T., Choi, C., Kim, C. H., Brown, J. L., Bolch, W. E., Zanzonico, P. B., Lewis, J. S. Tags: Basic Source Type: research

Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors
Conclusion: PET imaging with 124I-omburtamab antibody administered intraventricularly allows for noninvasive estimation of dose to CSF and normal organs. High CSF-to-blood absorbed-dose ratios are noted, allowing for an improved therapeutic index to leptomeningeal disease and reduced systemic doses. PET imaging–based estimates were less variable and more reliable than CSF sample–based dosimetry. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Pandit-Taskar, N., Zanzonico, P. B., Kramer, K., Grkovski, M., Fung, E. K., Shi, W., Zhang, Z., Lyashchenko, S. K., Fung, A. M., Pentlow, K. S., Carrasquillo, J. A., Lewis, J. S., Larson, S. M., Cheung, N.-K. V., Humm, J. L. Tags: Clinical Source Type: research

Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid-{beta} Mouse Model
Nonphysiologic overexpression of amyloid-β (Aβ) precursor protein in common transgenic Aβ mouse models of Alzheimer disease likely hampers their translational potential. The novel AppNL-G-F mouse incorporates a mutated knock-in, potentially presenting an improved model of Alzheimer disease for Aβ-targeting treatment trials. We aimed to establish serial small-animal PET of amyloidosis and neuroinflammation in AppNL-G-F mice as a tool for therapy monitoring. Methods: AppNL-G-F mice (20 homozygous and 21 heterogeneous) and 12 age-matched wild-type mice were investigated longitudinally from 2.5 to 10 mo of ...
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Sacher, C., Blume, T., Beyer, L., Peters, F., Eckenweber, F., Sgobio, C., Deussing, M., Albert, N. L., Unterrainer, M., Lindner, S., Gildehaus, F.-J., von Ungern-Sternberg, B., Brzak, I., Neumann, U., Saito, T., Saido, T. C., Bartenstein, P., Rominger, A. Tags: Basic Source Type: research

In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease
Conclusion: On the basis of the 11C-UCB-J PET results, hippocampal synaptic density was lower in APP/PS1 mice than in WT mice at baseline, and this deficit was normalized by treatment with saracatinib. These results support the use of 11C-UCB-J PET to identify disease-specific synaptic deficits and to monitor treatment effects in AD. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Toyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., Strittmatter, S. M., Carson, R. E. Tags: Basic Source Type: research

A Fully Automatic Technique for Precise Localization and Quantification of Amyloid-{beta} PET Scans
Conclusion: These findings suggest that processing the amyloid-β PET data in subjects’ native space can improve the accuracy of the computed SUVRs, as they are more closely associated with the histopathologic staining data than are the results of the conventional approach. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Tahmi, M., Bou-Zeid, W., Razlighi, Q. R. Tags: Clinical Source Type: research

Limits for Reduction of Acquisition Time and Administered Activity in 18F-FDG PET Studies of Alzheimer Dementia and Frontotemporal Dementia
Conclusion: Statistical results at a region and voxel level, as well as single-subject visual reads, reveal a considerable potential to reduce the typical 10-min acquisition time (by a factor of 4) without compromising diagnostic quality. Conversely, our data suggest that for a given acquisition time of 10 min and a similar effect size, the administered activity may be reduced to 50 MBq, resulting in an effective dose of less than 1 mSv for the PET examination. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Schiller, F., Frings, L., Thurow, J., Meyer, P. T., Mix, M. Tags: Clinical Source Type: research

Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies
Conclusion: Striatal presynaptic DAT function is clearly lower in PSP patients than in PD and MSA-P patients and is clearly lower in MSA-P patients than in MSA-C patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Kaasinen, V., Kankare, T., Joutsa, J., Vahlberg, T. Tags: Clinical Source Type: research

Imaging of Chemotherapy-Induced Acute Cardiotoxicity with 18F-Labeled Lipophilic Cations
Conclusion: 18F-MitoPhos showed pharmacokinetic parameters suitable for cardiac imaging. A significant dose response of cardiac uptake to doxorubicin treatment was observed before detectable biomarker alterations. 18F-MitoPhos is therefore a promising tracer for imaging chemotherapy-induced cardiotoxicity. To our knowledge, this is the first demonstration of radiolabeled lipophilic cations being used for the PET imaging of chemotherapy-induced cardiotoxicity and indicates the potential application of these compounds in this area. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: McCluskey, S. P., Haslop, A., Coello, C., Gunn, R. N., Tate, E. W., Southworth, R., Plisson, C., Long, N. J., Wells, L. A. Tags: Basic Source Type: research

Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
Conclusion: 68Ga-FAPI-04 represents a promising radiotracer for in vivo imaging of post-MI fibroblast activation. Noninvasive imaging of activated fibroblasts may have significant diagnostic and prognostic value, which could aid clinical management of patients after MI. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Varasteh, Z., Mohanta, S., Robu, S., Braeuer, M., Li, Y., Omidvari, N., Topping, G., Sun, T., Nekolla, S. G., Richter, A., Weber, C., Habenicht, A., Haberkorn, U. A., Weber, W. A. Tags: Basic Source Type: research

Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer
Conclusion: 18F-PSMA-11 can be safely administered and results in a mean effective dose of 12.8 ± 0.6 μSv/MBq. Therefore, the total radiation dose is lower than for other PSMA PET agents and in the same range as 18F-DCFPyL. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Piron, S., De Man, K., Van Laeken, N., DAsseler, Y., Bacher, K., Kersemans, K., Ost, P., Decaestecker, K., Deseyne, P., Fonteyne, V., Lumen, N., Achten, E., Brans, B., De Vos, F. Tags: Clinical Source Type: research

Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer
Conclusion: 18F-DCFPyL kinetics in PCa metastases are best described by a reversible 2-tissue-compartment model. Image-based TBRs were validated as a simplified method to quantify 18F-DCFPyL uptake and might be applied to clinical, whole-body PET scans. SUV does not provide reliable quantification of 18F-DCFPyL uptake. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 2, 2019 Category: Nuclear Medicine Authors: Jansen, B. H. E., Yaqub, M., Voortman, J., Cysouw, M. C. F., Windhorst, A. D., Schuit, R. C., Kramer, G. M., van den Eertwegh, A. J. M., Schwarte, L. A., Hendrikse, N. H., Vis, A. N., van Moorselaar, R. J. A., Hoekstra, O. S., Boellaard, R., Oprea-Lager, Tags: Clinical Source Type: research